Table: Sawai Pharmaceutical -Q1 group results (IFRS)
Aug 14 (Reuters)-
Sawai Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2018 Jun 30, 2017 Mar 31, 2019
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 45.30 38.15 172.50
(+18.7 pct) (+2.6 pct)
Operating 7.32 6.59 24.00
(+11.0 pct) (+8.1 pct)
Pretax 7.35 7.20 23.70
(+2.1 pct) (+17.0 pct)
Net 5.26 5.62 17.40
(-6.5 pct) (+24.1 pct)
EPS Basic 120.12 yen 152.46 yen 397.52 yen
EPS Diluted 120.04 yen 152.37 yen
Ann Div 130.00 yen 130.00 yen
-Q2 Div 65.00 yen 65.00 yen
-Q4 Div 65.00 yen 65.00 yen
NOTE - Sawai Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4555.T
Recent news on SAWAI group
See all newsTable: Sawai Group Holdings -Q1 group results (IFRS)
Table: Sawai Group Holdings -2025/26 group results (IFRS)
Brief: Silchester International Cuts Stake In Sawai Group Holdings To 5.82% From 6.83%, Regulatory Filing Shows
Table: Sawai Group Holdings -9-MTH group results (IFRS)
Table: Sawai Group Holdings 6-MTH group results (IFRS)